High‐Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta‐Analysis of Randomized Trials

替卡格雷 CYP2C19型 氯吡格雷 医学 经皮冠状动脉介入治疗 传统PCI 内科学 普拉格雷 阿司匹林 急性冠脉综合征 心肌梗塞 心脏病学 装载剂量 随机对照试验 新陈代谢 细胞色素P450
作者
Xiaoyan Sheng,Huijie An,Yong‐yang He,Yongfeng Ye,Jia‐lan Zhao,Sai Li
出处
期刊:Journal of Clinical Pharmacy and Therapeutics [Wiley]
卷期号:47 (8): 1112-1121 被引量:15
标识
DOI:10.1111/jcpt.13665
摘要

What is known and objective For patients after percutaneous coronary interventions (PCI), clopidogrel combined with aspirin is a conventional dual antiplatelet therapy (DAPT) method. Because the genetic polymorphism of CYP2C19 gene leads to clopidogrel resistance, guidelines for antiplatelet recommendations in CYP2C19 of ultrarapid metabolizers (UM), extended metabolizers (EM) and poor metabolizers (PM) are clear. However, there is no clear recommendation as to whether ticagrelor or double dose clopidogrel is the best antiplatelet regimen for CYP2C19 of intermediate metabolizers (IM). To evaluate the efficacy and safety of ticagrelor (combined with aspirin) and high-dose clopidogrel (combined with aspirin) in patients after PCI with CYP2C19 loss-of-function (LOF) alleles. Methods We searched the following databases to select RCTs of comparing ticagrelor with high-dose clopidogrel in patients after PCI with CYP2C19 LOF alleles: CNKI, Wanfang Data, PubMed, Clinical trials, Cochrane, Web of Science and Embase. Major adverse cardiovascular events (MACEs), platelet function and TIMI bleeding event were defined as the outcomes. revman 5.3 software was used to perform meta-analysis. Results and discussion A total of 14 RCTs with 2351 patients were enrolled. Meta-analysis showed that compared with high-dose clopidogrel, ticagrelor had reduced incidence of MACEs (OR = 0.32, 95% Cl: 0.23–0.44, p < 0.00001), stent thrombosis (OR: 0.24, 95%CI: 0.13–0.44, p < 0.00001), myocardial infarction OR: 0.42, 95%CI: 0.22–0.80, p = 0.008), revascularization (OR: 0.29, 95%CI: 0.10–0.82, p = 0.02) and unstable angina (OR: 0.47, 95%CI: 0.29–0.77, p = 0.003) in patients after PCI with CYP2C19 LOF alleles. A subgroup analysis showed that ticagrelor reduced the risk of MACEs compared with high-dose clopidogrel regardless of the type of metabolizer. Compared with high-dose clopidogrel, ticagrelor significantly reduced the risk of MACE with longer follow-up period (more than 3 months) without increasing the risk of bleeding (OR: 0.89, 95%CI: 0.53–1.49, p = 0.30), while elevated dyspnoea (OR: 5.62, 95%CI: 3.07–10.28, p < 0.00001). What is new and conclusions For patients carrying CYP2C19 LOF alleles after PCI, ticagrelor may be better than high-dose clopidogrel in reducing the risk of MACEs, while dyspnoea incidents should be alerted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_VZG7GZ的应助被柯科研采纳,获得10
刚刚
刚刚
Jasper的应助被jiashan采纳,获得10
1秒前
CL林完成签到 ,获得积分10
1秒前
zhonglv7完成签到,获得积分0
1秒前
YYL发布了新的文献求助10
1秒前
2秒前
李现完成签到,获得积分10
2秒前
2秒前
能干的绯发布了新的文献求助10
2秒前
所所的应助被zhinian28采纳,获得10
3秒前
小蘑菇的应助被寒冷鸭子采纳,获得10
3秒前
汉堡包的应助被哈哈采纳,获得50
3秒前
3秒前
英姑的应助被successful采纳,获得10
3秒前
4秒前
4秒前
贵金属LiLi发布了新的文献求助10
4秒前
momo123发布了新的文献求助10
5秒前
wt发布了新的文献求助10
5秒前
5秒前
喝口可乐的应助被CC7012采纳,获得10
5秒前
KJ发布了新的文献求助10
6秒前
天真醉薇完成签到,获得积分10
6秒前
qwer完成签到,获得积分10
6秒前
6秒前
心情不错发布了新的文献求助10
7秒前
7秒前
空空发布了新的文献求助10
7秒前
7秒前
阿罗完成签到,获得积分10
7秒前
7秒前
SciGPT的应助被朱文静采纳,获得10
7秒前
Tigher完成签到,获得积分10
8秒前
小灰灰完成签到,获得积分10
8秒前
酷波er的应助被JQ采纳,获得10
9秒前
luna发布了新的文献求助10
9秒前
万能图书馆的应助被jiashan采纳,获得10
9秒前
9秒前
坦率的匪发布了新的文献求助30
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181155
求助须知:如何正确求助?哪些是违规求助? 9571140
关于积分的说明 21816740
捐赠科研通 7777528
什么是DOI,文献DOI怎么找? 3433436
关于科研通互助平台的介绍 2557664
邀请新用户注册赠送积分活动 2479482